Stay at the forefront of drug discovery and therapeutic development with Drug Target Review. Dive into the latest research, industry analysis and technological advancements. Connect with world-renowned scientists and explore peer-reviewed articles, webinars, and more.

From January 2024, we will be bidding farewell to the current Drug Target Review magazine and launching a series of innovative offerings for the upcoming year.. Topic-specific eBooks: Delve into key topics and hear more from our editor and industry leaders

2025年1月14日 · New study explores safer antidepressants for pregnant women. 27 January 2025 | By Drug Target Review. A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects.

Drug Target Review is the essential resource for researchers and scientific leaders in drug discovery and early-phase therapeutic development.We ensure that the pharmaceutical and life science community are kept up-to-date with the latest research, developments and cutting-edge technological progression.

2023年3月29日 · This Drug Target Review issue provides you with a comprehensive view of the latest research and development shaping the future of drug discovery, covering cutting-edge technologies and breakthroughs that have the potential to revolutionise the field.From exploring new ways to reduce the number of animals used in scientific experiments, to developing more efficient and effective therapeutic ...

2025年1月16日 · Streamlining macrocyclic therapeutic development. Platforms such as PeptiDream’s drug discovery platform system 17 have facilitated easier synthesis and screening of macrocyclic peptide libraries for lead compounds (eg, the PD-L1 macrocycle from Figure 1). Another approach to macrocyclic library design is to generate pools of peptidic scaffolds that are designed to possess qualities such as ...

6 天之前 · Coherus announces positive Phase II results for liver cancer treatment. 31 January 2025 | By Drug Target Review. Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.

2024年10月29日 · news Breakthrough trial offers new hope for cystic fibrosis patients. 28 November 2024 | By Drug Target Review. A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.

2023年12月21日 · To access this content please login, create an account or continue as a guest. If you choose to login or create an account you won't have to complete the registration form, and you'll be able to access most of our content free-of-charge.

2023年6月27日 · This Drug Target Review issue provides exclusive insight into the cutting-edge world of biomedical breakthroughs and scientific exploration.With features on cell and gene therapy, CRISPR technology, cancer research, and the latest advancements in screening and imaging. Within these pages, we focus our attention to CRISPR, a revolutionary gene-editing tool that has taken the scientific ...